OTC Emergency Contraceptive Application Nearing FDA Panel Review
This article was originally published in The Tan Sheet
Executive Summary
Women's Capital Corporation's application to switch its Plan B emergency contraceptive from Rx to OTC status is expected to be considered by an FDA advisory panel in mid December
You may also be interested in...
Barr Plans Move To OTC Market With Plan B Emergency Contraceptive
Barr Laboratories will continue to pursue an Rx-to-OTC switch for the emergency contraceptive Plan B following its planned acquisition of the product
Barr Plans Move To OTC Market With Plan B Emergency Contraceptive
Barr Laboratories will continue to pursue an Rx-to-OTC switch for the emergency contraceptive Plan B following its planned acquisition of the product
Barr Plans Move To OTC Market With Plan B Emergency Contraceptive
Barr Laboratories will continue to pursue an Rx-to-OTC switch for the emergency contraceptive Plan B following its planned acquisition of the product